Bright Minds Biosciences Inc. DRUG
Updated: 8 Aug 2026
No signal published yet
We already track Bright Minds Biosciences and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Bright Minds Biosciences Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Bright Minds Biosciences free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In May 2026, the company reported its second-quarter financial results, ending the period with approximately CAD 309.7 million in cash following a USD 175 million public offering completed in January 2026. The capital is funding ongoing clinical development for its lead compound BMB-101 in epilepsy indications.
What Firelda Watch includes for Bright Minds Biosciences Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Bright Minds Biosciences Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Bright Minds Biosciences free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more